HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – HC Wainwright decreased their FY2025 EPS estimates for Enlivex Therapeutics in a report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.59) for the year, down from their prior forecast of ($0.58). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share.

Separately, D. Boral Capital reissued a “buy” rating and set a $13.00 price target on shares of Enlivex Therapeutics in a research report on Monday, March 3rd.

Enlivex Therapeutics Stock Down 3.7 %

ENLV stock opened at $1.05 on Wednesday. The company has a market cap of $22.48 million, a price-to-earnings ratio of -1.07 and a beta of 1.11. The business has a fifty day simple moving average of $1.10 and a 200-day simple moving average of $1.24. Enlivex Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.59.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new position in shares of Enlivex Therapeutics in the 4th quarter valued at $26,000. Renaissance Technologies LLC raised its holdings in shares of Enlivex Therapeutics by 112.6% during the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after buying an additional 84,203 shares during the period. Finally, Millennium Management LLC acquired a new position in Enlivex Therapeutics during the 4th quarter worth approximately $742,000. 1.02% of the stock is owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.